Phoenix Biotech Acquisition Corp.
Status: Deal Closed
U=S+W/2
W=S@11.50
| IPO Proceeds, $M | $175.00M |
|---|---|
| IPO Date | Oct 6, 2021 |
| CEO | Chris Ehrlich |
| Left Lead | Cantor Fitzgerald |
| IPO Cash in Trust | 102.0% |
| SPAC Tenor | 15 + 6 + 6 + 3 |
| IPO Sector |
Healthcare
Healthcare or healthcare related industries in the United States and Europe |
| IPO Geography | Global |
| Target Company | CERo Therapeutics |
| Deal Announced | Jun 5, 2023 |
| Deal Size, $M | $112.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Feb 8, 2024 |
| Amendment Vote | Jan 3, 2024 |
| Closing Date | Feb 14, 2024 |
Formerly PBAX
CERO
CEROW
| Price | $0.25 |
|---|---|
| Last closing price | $0.26 |
| H/L, today | $0.23 / $0.28 |
| Volume, today | 13,919,825 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Phoenix Biotech Acquisition Corp.:
- Structure and cap table
- 7 directors & officers
- 37 filings and events
- 1 underwriters
- 1 deal advisors
- 3 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Chris Ehrlich | 51 | CEO and Director |
| Daniel Geffken | 63 | CFO |
| Douglas Fisher | 45 | President |
| Brian G. Atwood | 68 | Director |
| Kathleen LaPorte | 59 | Director |
| Barbara Kosacz | 63 | Director |
| Caroline Loewy | 55 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Cantor Fitzgerald | BR | 15,500,000 | units |
| 15,500,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
5.00 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.